Janux Therapeutics, Inc.

NASDAQ (USD): Janux Therapeutics, Inc. (JANX)

Last Price

61.11

Today's Change

-0.39 (0.63%)

Day's Change

60.26 - 63.86

Trading Volume

717,648

Overview

Market Cap

3 Billion

Shares Outstanding

57 Million

Avg Volume

949,369

Avg Price (50 Days)

52.36

Avg Price (200 Days)

46.49

PE Ratio

-52.23

EPS

-1.17

Earnings Announcement

07-Mar-2025

Previous Close

61.50

Open

61.24

Day's Range

60.26 - 63.86

Year Range

7.79 - 71.71

Trading Volume

738,677

Price Change Highlight

1 Day Change

-0.63%

5 Day Change

-4.20%

1 Month Change

19.59%

3 Month Change

22.20%

6 Month Change

45.50%

Ytd Change

454.54%

1 Year Change

468.47%

3 Year Change

234.48%

5 Year Change

142.98%

10 Year Change

142.98%

Max Change

142.98%

News and Blogs
Latest Hottest Following

No result.

Company Profile

Sector: Healthcare - Healthcare

Industry: Biotechnology

Description:

Janux Therapeutics, Inc., a biopharmaceutical company, develops therapeutics based on proprietary Tumor Activated T Cell Engager (TRACTr) platform technology to treat patients suffering from cancer. The company's lead TRACTr product candidates that are in preclinical or discovery stage target prostate-specific membrane antigen, epidermal growth factor receptor, and trophoblast cell surface antigen 2. Janux Therapeutics, Inc. is also developing a Tumor Activated Immunomodulator (TRACIr) costimulatory bispecific product candidate against programmed death-ligand 1 and CD28 designed to improve the anti-tumor activity of T cells. In addition, its EGFR-TRACTr is designed to target EGFR in many cancer types with multiple approved monoclonal antibodies. The company was incorporated in 2017 and is headquartered in La Jolla, California.

Discussions
Be the first to like this. Showing 0 of 0 comments
Post a Comment